The Myopia Podcast
Introducing "The Myopia Podcast" hosted by David Kading, a leading myopia educator and founder of a renowned myopia clinic in Seattle. This bite-sized podcast is specifically designed to empower and educate eyecare providers in the field of myopia management.
In each episode, David Kading dives into the latest research, innovations, and clinical methods to enhance the effectiveness of managing myopic children. Whether you're an optometrist, ophthalmologist, or a passionate eyecare professional, this podcast provides invaluable insights and practical knowledge to elevate your expertise.
With a perfect blend of education and entertainment, "The Myopia Podcast" keeps you engaged throughout. David's expertise and engaging style make complex concepts accessible and relatable. The episodes are thoughtfully curated to deliver concise and impactful content, ensuring that each episode can be enjoyed within a convenient timeframe of under 30 minutes.
Stay up-to-date with the rapidly evolving field of myopia management as "The Myopia Podcast" unveils expert interviews, case studies, success stories, and evidence-based strategies. Discover new perspectives, learn about emerging technologies, and explore innovative practice management techniques to optimize your approach in managing myopic children.
Join the community of eyecare providers dedicated to providing the best care for their myopic patients. Tune in to "The Myopia Podcast" and unlock a wealth of knowledge that will transform your practice and make a lasting impact on the lives of your young patients.
The Myopia Podcast
#79 What do we know about Atropine! with Mark Bullimore and Patrick Johnson from Sydnexis
I want to give a special thank you to Syndexis for being a sponsor of The Myopia Podcast. If you're not aware Syndexis is a biopharmaceutical company that was founded in 2014, they're based in Del Mar California.
Their mission is to develop a proprietary stable accurate effective
safe topical eye drop to treat the progression of myopia in children
and to minimize the risk of co-morbidities later in life. They're on the cusp of a new treatment paradigm to fight myopia progression in children, they're in the late stage of their pivotal phase 3 trial for their investigation medication SYD1 01.
The Myopia Podcast and myself are rooting for them and are watching Syndexis closely.
Stay tuned!